Pharmagreen Competitors

Pink Sheets . USA . 
Stock . Pharmagreen Biotech
PHBI Stock  USD 0  0.0001  3.45%   
Analyzing Pharmagreen Biotech competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Pharmagreen Biotech to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Pharmagreen Biotech Correlation with its peers.

Pharmagreen Biotech vs Cann American Correlation

Very good diversification

The correlation between Pharmagreen Biotech and CNNA is -0.23 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Pharmagreen Biotech and CNNA in the same portfolio, assuming nothing else is changed.

Moving together with Pharmagreen Pink Sheet

  0.8MKKGY Merck KGaA ADRPairCorr
  0.75MKGAF MERCK KommanditgesellsPairCorr
  0.72TAK Takeda PharmaceuticalPairCorr
  0.71TKPHF Takeda PharmaceuticalPairCorr

Moving against Pharmagreen Pink Sheet

  0.52BKRKF PT Bank RakyatPairCorr
  0.36PTAIF PT Astra InternationalPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.00011.23
Details
Intrinsic
Valuation
LowRealHigh
0.00011.23
Details
Naive
Forecast
LowNextHigh
0.000058011.23
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
000
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Pharmagreen Biotech. Your research has to be compared to or analyzed against Pharmagreen Biotech's peers to derive any actionable benefits. When done correctly, Pharmagreen Biotech's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Pharmagreen Biotech.

Pharmagreen Biotech Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Pharmagreen Biotech and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Pharmagreen and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Pharmagreen Biotech does not affect the price movement of the other competitor.

High positive correlations

CBDY
+ 0.44
ALID
ALID
+ 0.38
MSTH
CNNA
+ 0.35
MSTH
CNNA
+ 0.3
ALID
CBDY
+ 0.16
MSTH
CNNA
+ 0.16
CBDY
  

High negative correlations

APPB
- 1.0
LVVEF
CPMD
- 0.5
ALID
MJNA
- 0.39
ALID
MJNA
- 0.29
CBDY
CPMD
- 0.25
MSTH
CNNA
- 0.21
MJNA

Risk-Adjusted Indicators

There is a big difference between Pharmagreen Pink Sheet performing well and Pharmagreen Biotech Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Pharmagreen Biotech's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
MSTH  21.81  10.46  0.00  1.71  0.00 
 0.00 
 0.00 
 0.00 
 721.39 
ALID  2.85 (1.51) 0.00 (0.94) 0.00 
 0.00 
 0.00 
 0.00 
 95.50 
EXMT  11.13  1.78  0.06 (2.53) 11.28 
(42.59)
 33.33 
(25.00)
 133.33 
CBDY  13.01  1.23  0.06  0.30  13.86 
(21.85)
 35.71 
(28.57)
 100.00 
LVVEF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CPMD  12.51  2.03  0.09 (2.18) 13.07 
(31.50)
 38.46 
(23.86)
 159.29 
SRUTF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
MJNA  26.22  7.17  0.15 (2.19) 20.68 
(79.17)
 100.00 
(50.00)
 266.67 
APPB  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CNNA  111.13  54.03  0.91  1.39  18.94 
(568.42)
 66.67 
(29.17)
 2,040 

Pharmagreen Biotech Competitive Analysis

The better you understand Pharmagreen Biotech competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Pharmagreen Biotech's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Pharmagreen Biotech's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
PHBI MSTH ALID EXMT CBDY LVVEF CPMD MJNA APPB CNNA
 3.45 
 0 
Pharmagreen
 0.00 
 0.01 
Mystic
 0.00 
 0.0005 
Allied
 33.33 
 0.0004 
Anything
 6.25 
 0 
Target
 0.00 
 0 
Yooma
 4.76 
 0 
CannaPharmaRx
 33.33 
 0.0002 
Medical
 0.00 
 0.0001 
Applied
 0.00 
 0 
Cann
Market Volatility
(90 Days Market Risk)
Out of control
Out of control
Out of control
Out of control
Out of control
Very steady
Out of control
Out of control
Very steady
Out of control
Market Performance
(90 Days Performance)
Fair
Weak
Weakest
Fair
Soft
Weakest
Mild
Good
Weakest
Good
Odds of Financial Distress
(Probability Of Bankruptcy)
Small
High
Risky
High
High
High
Small
Low
Risky
High
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Sell
Current Ratio
0.1
0.44
0.05
0.02
0.17
1.12
N/A
1.92
0.11
20.16
Net Asset
208.97 K
N/A
5.79 M
2.31 M
13.06 M
36.59 M
114.33 K
N/A
3.65 M
N/A
Profit Margin
N/A
-0.29
N/A
N/A
N/A
-2.07
N/A
0.15
N/A
N/A
EBITDA
(828.26 K)
(1.13 M)
(14.22 M)
(478.99 K)
2.23 M
(11.26 M)
(6.07 M)
1.45 M
(1.99 M)
(275.98 K)
Current Valuation
3.12 M
N/A
27.14 M
1.96 M
4.2 M
12.48 M
20.13 M
62.53 M
4.4 K
48
Operating Margin
N/A
-0.18
-26.04
-1.9
N/A
-0.55
N/A
-0.0376
-5.72
-21.26
Price To Book
N/A
N/A
52.5
N/A
7.83
0.0624
11.05
0.55
0.31
7.0E-4
Retained Earnings
N/A
N/A
N/A
(7.96 M)
N/A
N/A
(28.64 M)
31.14 M
N/A
(4 M)
Current Asset
N/A
N/A
N/A
2 K
N/A
N/A
233 K
14.02 M
N/A
N/A
Beta
1.44
N/A
0.25
0.62
-0.51
1.85
0.21
1.12
2213.92
1.21
Number Of Employees
4
78
6
6
61
2
4
91
25
1
Shares Outstanding
454.76 M
N/A
97.04 M
N/A
617.03 M
100.86 M
257.57 M
3.44 B
22 M
4.44 K
Cash Flow From Operations
(426.57 K)
794.76 K
(4.28 M)
(1.91 M)
100.12 K
(10.97 M)
(2.41 M)
86.86 M
(905.05 K)
(244.54 K)
Total Debt
119.47 K
1.11 M
4.81 M
1.29 M
1.72 M
10.89 M
14.96 M
10.41 M
25 K
N/A
Return On Equity
N/A
-0.2
-43.44
N/A
-23.05
-0.96
-2.51
0.12
-2.22
-2.6
Z Score
4.5
N/A
-3.0
-4.2
0.6
N/A
N/A
3.0
N/A
-12.6
Return On Asset
-2.3
-0.0512
-0.65
N/A
-0.0596
-0.11
-0.26
-0.0146
-0.64
-0.85
Book Value Per Share
-0.004
0.24
-0.015
-0.004
-0.005
0.12
-0.068
0.02
0.016
0.001
Current Liabilities
N/A
N/A
N/A
2.04 M
N/A
N/A
518 K
5.37 M
N/A
384 K
Total Asset
208.97 K
N/A
5.79 M
2.31 M
13.06 M
36.59 M
114.33 K
209.53 M
3.65 M
417 K
Debt To Equity
N/A
0.039
1.19
0.009
1.82
1.08
7.05
0.13
1.01
0.14
Shares Owned By Institutions
N/A
N/A
N/A
N/A
N/A
0.78
N/A
N/A
N/A
N/A
Market Capitalization
2.96 M
N/A
29.06 M
169.22 K
2.47 M
749.88 K
2.83 M
56.49 M
2.2 K
421
Price To Earning
N/A
N/A
N/A
-0.53
N/A
N/A
N/A
5.25
N/A
N/A
Price To Sales
N/A
N/A
130.8
0.66
340.13
0.0787
N/A
0.86
0.0026
0.0306
Net Income
(875.48 K)
(1.32 M)
(15.54 M)
(575.2 K)
272.88 K
(33.12 M)
(8.83 M)
84.4 M
(2.63 M)
(249.82 K)
Earnings Per Share
-0.005
N/A
-0.21
-0.003
N/A
-0.36
-0.12
0.002
N/A
-0.001
Shares Owned By Insiders
18.63
N/A
53.29
N/A
11.37
2.0
1.12
N/A
32.23
9.5
Revenue
N/A
14.95 M
165.6 K
46.83 K
N/A
10.18 M
N/A
58.98 M
707.06 K
13.23 K
Working Capital
N/A
N/A
N/A
(2.04 M)
N/A
N/A
(285 K)
8.65 M
(19.81 K)
(384 K)
Cash And Equivalents
24.26 K
84.84 K
80.69 K
342
114.21 K
1.79 M
5.18 K
4.68 M
21.27 K
59.87 K
Cash Per Share
N/A
N/A
N/A
N/A
N/A
0.02
N/A
N/A
N/A
N/A
Gross Profit
N/A
6.4 M
74.12 K
113.04 K
5 K
2.7 M
N/A
57.73 M
528.31 K
16.71 K
Day Typical Price
0.0028
0.011
5.0E-4
4.0E-4
0.0015
0.0011
0.0039
2.0E-4
1.0E-4
0.002
Accumulation Distribution
N/A
N/A
N/A
0.25
N/A
N/A
0.075
0.5
N/A
N/A
Market Facilitation Index
N/A
N/A
N/A
1.0E-4
N/A
N/A
3.0E-4
1.0E-4
N/A
N/A
Daily Balance Of Power
0
0.0
0.0
1.0
0
0.0
(0.67)
(1.00)
0.0
0.0
Period Momentum Indicator
(0.0001)
N/A
N/A
1.0E-4
(0.0001)
N/A
(0.0002)
(0.0001)
N/A
N/A
Rate Of Daily Change
0.97
1.0
1.0
1.33
0.94
1.0
0.95
0.67
1.0
1.0
Day Median Price
0.0028
0.011
5.0E-4
4.0E-4
0.0015
0.0011
0.0039
1.0E-4
1.0E-4
0.002
Price Action Indicator
(0.00005)
N/A
N/A
1.0E-4
(0.00005)
N/A
1.0E-4
N/A
N/A
N/A
Relative Strength Index
52.21
50.0
N/A
56.44
45.68
N/A
46.62
49.19
N/A
52.27
Coefficient Of Variation
971.96
792.97
(812.40)
1159.24
1345.87
N/A
1192.94
600.69
N/A
580.6
Mean Deviation
7.88
21.81
2.85
11.13
13.01
N/A
12.51
26.22
N/A
111.13
Jensen Alpha
1.07
10.46
(1.51)
1.78
1.23
N/A
2.03
7.17
N/A
54.03
Total Risk Alpha
0.6083
6.58
(2.02)
0.7676
0.481
N/A
0.8399
5.01
N/A
39.87
Sortino Ratio
0.1174
N/A
N/A
0.0608
0.0642
N/A
0.0911
0.1463
N/A
0.912
Downside Variance
91.18
N/A
N/A
802.47
448.16
N/A
463.85
2305.56
N/A
3687.78
Standard Deviation
11.33
84.76
11.75
20.49
18.89
N/A
23.93
42.47
N/A
321.82
Kurtosis
4.28
64.72
66.0
7.63
1.36
N/A
9.17
6.26
N/A
30.86
Potential Upside
18.75
N/A
N/A
33.33
35.71
N/A
38.46
100.0
N/A
66.67
Treynor Ratio
0.4496
1.71
(0.94)
(2.53)
0.3022
N/A
(2.18)
(2.19)
N/A
1.39
Maximum Drawdown
64.69
721.39
95.5
133.33
100.0
N/A
159.29
266.67
N/A
2040.0
Variance
128.38
7184.78
138.17
419.9
357.01
N/A
572.79
1803.94
N/A
103567.98
Market Risk Adjusted Performance
0.4596
1.72
(0.93)
(2.52)
0.3122
N/A
(2.17)
(2.18)
N/A
1.4
Risk Adjusted Performance
0.0838
0.1011
(0.08)
0.072
0.0634
N/A
0.0703
0.1302
N/A
0.1345
Skewness
1.5
8.01
(8.12)
1.92
0.687
N/A
2.24
1.9
N/A
5.61
Semi Deviation
7.47
N/A
N/A
11.28
13.86
N/A
13.07
20.68
N/A
18.94
Information Ratio
0.0989
0.1256
(0.13)
0.0841
0.0719
N/A
0.0819
0.1654
N/A
0.1721
Value At Risk
(15.62)
N/A
N/A
(25.00)
(28.57)
N/A
(23.86)
(50.00)
N/A
(29.17)
Expected Short fall
(11.57)
N/A
N/A
(42.59)
(21.85)
N/A
(31.50)
(79.17)
N/A
(568.42)
Downside Deviation
9.55
N/A
N/A
28.33
21.17
N/A
21.54
48.02
N/A
60.73
Semi Variance
55.79
N/A
N/A
127.17
192.09
N/A
170.76
427.81
N/A
358.6

Pharmagreen Biotech Competition Performance Charts

Five steps to successful analysis of Pharmagreen Biotech Competition

Pharmagreen Biotech's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Pharmagreen Biotech in relation to its competition. Pharmagreen Biotech's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Pharmagreen Biotech in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Pharmagreen Biotech's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Pharmagreen Biotech, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Pharmagreen Biotech position

In addition to having Pharmagreen Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Theme ETFs Thematic Idea Now

Theme ETFs
Theme ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Theme ETFs theme has 484 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Theme ETFs Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Pharmagreen Pink Sheet

Pharmagreen Biotech financial ratios help investors to determine whether Pharmagreen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmagreen with respect to the benefits of owning Pharmagreen Biotech security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY